Menarini to enhance BPDCN detection with VisualDx’s link
The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the ...
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People...
The Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc.
The Manila Times1d
Star Equity Holdings, Inc. Announces 2024 Fourth Quarter and Full Year Financial Results
Star Equity Holdings, Inc. is a diversified holding company with three divisions: Building Solutions, Energy Services, and ...
Targeted Oncology3d
The Role of CD123 Targeted Therapy (tagraxofusp) in the Evolving Treatment Landscape for BPDCN
An expert discusses how medical professionals have integrated tagraxofusp into blastic plasmacytoid dendritic cell neoplasm (BPDCN) treatment, leveraging its CD123-targeted efficacy per 0114 trial ...
The Clinton Herald3d
TO YOUR GOOD HEALTH: Over-the-counter treatments don't help man's enlarged prostate
I am 71, and I recently saw my urologist for urinating a lot and not getting enough sleep. He performed a flow test and a ...
Healio4d
VIDEO: Recent approval ‘adds another option’ for patients with myelofibrosis
In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.